Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a clinical-stage biopharmaceutical leader pioneering neuroscience therapies for central nervous system disorders. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory developments, strategic partnerships, and quarterly results. Our aggregation ensures timely access to material information about CERE's neuropharmacology pipeline targeting Parkinson's, Alzheimer's, and schizophrenia.
All content is verified at source to maintain compliance with financial disclosure standards. Bookmark this page for streamlined tracking of Cerevel's advancements in receptor-specific therapies and neuroscience innovation.
Cerevel Therapeutics (Nasdaq: CERE) announced key presentations at the American Academy of Neurology (AAN) Annual Meeting from April 2-7, 2022. Highlights include an oral presentation showcasing preclinical data on darigabat, demonstrating significant antiepileptic effects in drug-resistant focal seizures, comparable to diazepam. The company also revealed findings on tavapadon, a treatment for Parkinson’s disease, emphasizing its consistent pharmacokinetic profile across Phase 1 trials. Cerevel is focused on advancing its neuroscience drug pipeline to address unmet medical needs.
Cerevel Therapeutics (Nasdaq: CERE) announced that its CEO, Tony Coles, M.D., will participate in a fireside chat at the Stifel 4th Annual CNS Day on March 29, 2022, at 9:00 a.m. EDT. The event will highlight the company's commitment to addressing neuroscience diseases through its diversified pipeline, which includes six clinical-stage investigational therapies targeting conditions like schizophrenia and Parkinson’s disease. A live webcast will be available on Cerevel's investor relations website, along with a replay.
Cerevel Therapeutics announced positive results from a Phase 1 trial of darigabat for acute anxiety and is on track to initiate two Phase 2 trials of emraclidine for schizophrenia by mid-2022. The trials will involve 372 patients each, with results expected in the first half of 2024. Cerevel reported a cash position of $618 million as of December 31, 2021, a significant increase from $383.6 million in 2020. R&D expenses rose to $161.9 million, while G&A expenses grew to $58.2 million, reflecting ongoing investments in clinical programs and operations.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its fourth quarter 2021 financial results on March 1, 2022, before U.S. markets open. The company will host a conference call at 8:00 a.m. ET the same day to discuss the results and recent business updates. Interested parties can access the call by dialing designated numbers or via a live webcast on the company's investor website. Cerevel focuses on neuroscience diseases and has a diversified pipeline of investigational therapies.
Cerevel Therapeutics announced positive results from a Phase 1 trial of darigabat, a novel GABAA receptor PAM, showing significant anxiolytic effects in healthy volunteers. Both the 7.5 mg and 25 mg doses demonstrated a statistically significant improvement in Panic Symptoms List scores after eight days compared to placebo. The trial was well-tolerated with no serious adverse events reported. Cerevel plans to advance darigabat for anxiety-related disorders and is also conducting a Phase 2 trial for focal epilepsy. These developments position darigabat as a potential treatment innovation in anxiety management.
Cerevel Therapeutics announces emraclidine as the international nonproprietary name for CVL-231, an M4-selective positive allosteric modulator for schizophrenia. The company plans to initiate a Phase 2 program by mid-2022, with expected data in the first half of 2024. The Phase 1 trial for darigabat in acute anxiety has been completed, with data anticipated shortly. Additionally, the Phase 2a data for CVL-871 in dementia-related apathy is now expected in 1H 2023, delayed from 2H 2022 due to COVID-19. Cerevel's cash is projected to fund operations into 2024.
Cerevel Therapeutics (Nasdaq: CERE) announced that CEO Tony Coles will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET. Joining him will be CMO Raymond Sanchez and CSO John Renger for the Q&A session. Investors can access the live webcast on the company's investor relations website, with a replay available afterward. Cerevel focuses on treating neuroscience diseases, possessing a pipeline of six clinical-stage therapies aimed at conditions like Parkinson's, epilepsy, and schizophrenia.
Cerevel Therapeutics (CERE) and Herophilus have initiated a multi-year collaboration focusing on schizophrenia treatment using innovative brain organoids and deep phenotyping technologies. This partnership aims to uncover disease mechanisms and develop therapies that could significantly improve or even reverse schizophrenia symptoms. By integrating human genetics into advanced testing models, they hope to enhance therapeutic discovery and validation processes. Cerevel's pipeline includes multiple clinical-stage therapies targeting various neuroscience diseases, including schizophrenia.
Cerevel Therapeutics (Nasdaq: CERE) reported significant updates on its pipeline and third-quarter financial results for 2021. The company expects Phase 1 data for darigabat in acute anxiety by Q1 2022 and has submitted additional PK/PD data for CVL-231 in schizophrenia for presentation at the ACNP meeting. Cerevel's cash reserves stand at $669.7 million, sufficient to fund operations into 2024. R&D expenses rose to $114 million year-to-date, reflecting ongoing trial execution. General and administrative costs increased as well, driven by public company and personnel expenses.
Cerevel Therapeutics (Nasdaq: CERE) is set to participate in four virtual investor conferences in November and December 2021. The events include the Guggenheim 3rd Annual Neuro/Immunology Conference on November 15, followed by the Stifel 2021 Virtual Healthcare Conference on November 16, the Jefferies London Healthcare Conference on November 18, and the Evercore ISI HealthCONx Conference on December 1. Live audio webcasts of the fireside chats will be available on their investor relations website, with replays also provided.